General MedicationsINJECTIONGeneric
AMIPAQUE
METRIZAMIDE
Standard Dose
6.75GM/VIAL
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Discontinued
Summary
Approval overview AMIPAQUE is listed in Drugs@FDA under application 017982 (NDA).
Review priority: PRIORITY Marketing status: Discontinued Active ingredient METRIZAMIDE Form and strength INJECTABLE;INJECTION - 6.75GM/VIAL Sponsor GE HEALTHCARE Submission history Latest submission status date: 1989-05-31 00:00:00.
Structured Monograph
Clinical summary
Approval overview AMIPAQUE is listed in Drugs@FDA under application 017982 (NDA). Review priority: PRIORITY Marketing status: Discontinued Active ingredient METRIZAMIDE Form and strength INJECTABLE;INJECTION - 6.75GM/VIAL Sponsor GE HEALTHCARE Submission history Latest submission status date: 1989-05-31 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: PRIORITY
Interaction Notes
- No interaction notes stored yet.